Alkermes plc Enhances Acquisition Offer for Avadel Pharmaceuticals to $22.50 per Share

Alkermes Expands Portfolio with Enhanced Offer for Avadel Pharmaceuticals

Alkermes plc has recently increased its offer to acquire Avadel Pharmaceuticals plc, presenting a total transaction value of up to $22.50 per share. This enhanced proposal includes $21.00 in cash and a contingent value right (CVR) that could yield an additional $1.50 per share, contingent on the FDA’s approval of LUMRYZ™ for treating idiopathic hypersomnia in adults by the end of 2028. The new offer values Avadel at approximately $2.37 billion, contingent on the potential milestone payment. Both companies' boards have approved the transaction, which is expected to close in the first quarter of 2026, pending certain conditions.

This strategic acquisition emphasizes Alkermes' commitment to broadening its pharmaceutical portfolio and advancing its capabilities in addressing complex medical conditions. The move comes after Avadel received an unsolicited acquisition proposal from H. Lundbeck A/S, which initially created uncertainty regarding the potential deal. However, after thorough evaluation, Avadel's board determined that the Lundbeck proposal did not fulfill the requirements necessary to be considered superior, allowing them to continue negotiations with Alkermes. This decision highlights Alkermes' competitive standing in the pharmaceutical industry and its ability to navigate the challenges associated with corporate acquisitions effectively.

The amendment to the definitive transaction agreement executed on November 18, 2025, signifies a crucial step in solidifying the deal, ensuring that both parties are aligned on the terms of the acquisition. By pursuing this acquisition, Alkermes positions itself not only to enhance its product offerings but also to diversify its therapeutic focus, which could lead to increased market share and improved treatment solutions for patients suffering from rare conditions like idiopathic hypersomnia.

In addition to this acquisition, Alkermes continues to focus on delivering innovative therapies that address unmet medical needs. The company’s strategic maneuvers underscore its commitment to research and development, setting the stage for potential breakthroughs in treatment options. As the pharmaceutical landscape evolves, Alkermes remains well-positioned to capitalize on growth opportunities within the industry.

Ultimately, the acquisition of Avadel Pharmaceuticals could prove to be a pivotal moment for Alkermes, reinforcing its mission to transform the lives of patients through the development of meaningful therapies.